Elanco Animal Health Incorporated (ELAN) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Greenfield, IN, United States. The current CEO is Jeffrey N. Simmons.
ELAN has IPO date of 2018-09-20, 9,000 full-time employees, listed on the NYSE, a market capitalization of $11.99B.
Elanco Animal Health Incorporated is a global animal health company that innovates, develops, manufactures, and markets pharmaceutical and nutritional products for both companion animals and farm animals. For pets, the company offers disease prevention products such as parasiticides and vaccines under brands including Seresto, Advantage, and Advantix, as well as therapeutic treatments for pain, osteoarthritis, and dermatological conditions. In the farm animal sector, Elanco provides vaccines, antibiotics, parasiticides, and nutritional health products for poultry, aquaculture, ruminant, and swine production, with key brands including Rumensin and Baytril. The company distributes its products through veterinarians, third-party distributors, and direct relationships with farm animal producers. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a diverse customer base spanning veterinary clinics and agricultural operations worldwide.
